Papers
5
Total Citations
58
H-Index
3
About
Yuliuming Wang is a leading figure in the advancement of robotic colorectal surgery, with a focused research program dedicated to evaluating emerging surgical platforms against established global standards. His primary contribution lies in the rigorous clinical validation of the Chinese-made KangDuo Surgical Robotic System (KD-SR-01) for the treatment of colorectal cancer. Through a series of prospective cohort studies and multicenter randomized controlled trials, Wang has systematically demonstrated that the KangDuo system is noninferior to the industry-leading da Vinci Si and Xi systems in terms of short-term oncologic outcomes and surgical quality. His landmark 2023 prospective cohort study (26 citations) and the subsequent 2024 multicenter noninferiority trial (20 citations) provide critical evidence supporting the adoption of this domestic robotic platform. Wang’s work extends to specialized populations, including elderly patients, and explores the physiological impact of robotic surgery by analyzing surgical stress responses. By generating high-quality comparative data, his research is directly shaping the landscape of minimally invasive colorectal surgery, fostering competition, and improving access to advanced robotic technology in China and beyond.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5